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Abstract 
Background: There is a constant increase of joint arthroplasties performed, with an infectious risk 
of 1-2%. Different therapeutic options for prosthetic-joint infections exist, but surgery remains 
essential. With a two-stage exchange procedure, a success rate above 90% can be expected. 
Currently, there is no consensus regarding the optimal interval duration between explantation and 
reimplantation. This retrospective study aimed to assess the economic impact of a two-stage 
exchange from a single-hospital perspective. 
Methods: 21 patients who have undergone a two-stage exchange of a hip or knee prosthetic-joint 
infection at the University Hospital of Lausanne (Switzerland) from 2012 to 2013 were included. The 
revenues earned according to the Swiss Diagnosis Related Groups (SwissDRG) system introduced 
in 2012 and the costs were compared for each hospital stay. 
Results: The remuneration ranged from 26'806 to 42'978 Swiss francs (CHF) (~ 22’905-36’723 
EUR, median 36’338 CHF, ~ 31’049 EUR). The median total cost per patient was 76'000 CHF (~ 
65’000 EUR) (51'151 to 118'263; hip median 79’744, knee median 66’708). The main determinant of 
the costs was the length of the hospital stay. Revenues never covered all the costs, even with a 
short-interval procedure. The hospital lost a median of 35’000 CHF per patient (~ 30’000 EUR) 
(22'280 to 64'666). 
Conclusion: The current DRG system may not be specific enough for rewarding prosthetic-joint 
infections. Several options could be considered to act on the length of the hospital stay. In order to 
cover costs in complicated cases, such as prosthetic-joint infections, more specific DRGs are 
needed. 
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Introduction 
In Switzerland, more than 35’000 joint 
arthroplasty procedures are performed every year to 
improve the quality of life of an aging population.[1] 
Prosthetic-joint infections (PJI) are rare, with an 
incidence of 1-2%, but they represent serious 
complications in terms of morbidity and costs.[2] For 
adequate care of a patient, the surgeon has to choose 
between different therapeutic options, of which 
surgery remains essential. If a replacement of the 
infected joint arthroplasty is needed, a success rate 
above 90% can be expected with a two-stage 
procedure.[2] Two-stage revision includes removal of 
all foreign material, debridement, and reimplantation 
of a new prosthesis after a variable period of time to 
manage the infection. Intravenous antimicrobial 
treatment is administered followed by oral therapy 
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for a total of three months. Currently, there is no 
consensus regarding the optimal interval duration 
between the prosthesis explantation and reimplant-
ation procedure. The interval varies from two weeks 
to several months [Figure 1].[2,3] 
The economic consequences associated with 
treating periprosthetic infections are known. Already 
in 1990, Sculco et al. demonstrated that the inadequate 
reimbursement of the treatment of prosthetic-joint 
infections causes an economic burden to the hospital 
and consequently to the healthcare system.[4,5] In 
addition, between 1990 and 2004, a nearly two-fold 
increase in the incidence of these infections was 
observed in the United States.[6] The annual cost of 
infected revisions for US hospitals is projected to 
exceed 1.6 billion dollars by 2020.[7] 
The Swiss Diagnosis Related Groups 
(SwissDRG; SDRG) tariff system for acute somatic 
inpatient hospital services was introduced in January 
2012.[8] It consistently sets the remuneration of 
hospital services according to the latest revision of the 
Swiss Health Insurance law (LAMal) voted in 2007. 
The DRG system was invented as a patient 
classification system in 1967 by the scientists Robert 
Barclay Fetter and John Devereaux Thompson at the 
University of Yale. It was first implemented in 1983 in 
the USA to measure each individual patient's 
consumption of hospital resources.[5,9,10] Since then, 
DRGs have been introduced in many countries. 
SwissDRG is supposed to provide homogenous, 
transparent and comparable hospital remuneration, 
improve efficiency and reduce costs.[10] In it, each 
hospital stay is assigned to a group of pathologies, at 
the end of hospitalization, and reimbursed by the 
insurance companies at a fixed rate.[11] This form of 
remuneration compensates hospitals for cases, taken 
as a whole. Therefore, hospitals are not paid for each 
therapeutic act.[12] The groups include admissions 
for similar diagnoses with treatments costs supposed 
to be comparable. A software with a classification 
algorithm (grouper) allocates an inpatient admission 
in a SDRG. This allocation applies to several criteria, 
including the condition that has requested most of the 
resources (principal diagnosis) which does not always 
match the hospitalization pattern [Figure 2].[8] Today 
974 SDRGs are defined. 
The literature contains few economic evaluations 
of the revenues from the treatment of prosthetic-joint 
infections.[5,13] This retrospective study intended to 
assess the economic impact of a two-stage exchange 
from a single-hospital perspective. We compared the 
revenues and the costs of each cases at the University 
Hospital of Lausanne in Switzerland from 2012, the 
year when the DRG system was introduced in 
Switzerland, to 2013. 
 
Figure 1. Two-stage exchange. (Adapted from [1]) 
 
 
Figure 2. SDRG classification algorithm. (Adapted from [8]) 
 
Methods 
Patients 
The inclusion criteria were to have a two-stage 
exchange from January 2012 to December 2013, with a 
single stay at the University Hospital of Lausanne  
(CHUV) and a SDRG expected for a prosthetic-joint 
infection [Table 1]. Patients with multiple stays (e.g. 
temporary transfer to a peripheral hospital) were 
excluded for sake of consistent comparison [Figure 3]. 
Patients with another SDRG (e.g. post-operative 
transplant) were excluded as well. Data for the 
included patients was extracted from electronic files 
and retrospectively analyzed using standard software 
(Microsoft Excel, IBM SPSS). 
Revenues 
All economic data were obtained in Swiss francs 
(CHF) and converted to Euros (EUR), with an 
exchange rate of 1 CHF equivalent to 0.8545 EUR. The 
revenue is the remuneration obtained by the hospital 
for each hospital stay. Each SDRG has a number of 
points (cost-weight), according to the gravity of the 
group's pathologies [Table 1]. The cost-weights are 
calculated measuring the cost for treatment of each 
SDRG in a sample of hospitals. They are adjusted 
annually. The base rate corresponds to the price of a 
SDRG point and is negotiated every year between 
each hospital and its insurance companies. The base 
rate was 10'400 CHF (~ 8’886 EUR) in 2012 and 2013. 
 J. Bone Joint Infect. 2018, Vol. 3 
 
http://www.jbji.net 
251 
The remuneration is obtained by multiplying the 
number of points (cost-weight) by the current price of 
the point (base rate) [Figure 4].[8] 
For each SDRG, a "normal" length of hospital 
stay is defined. The cases in which the length of stay 
lays between the limits are qualified inliers. To 
minimize the economic incentive to refer a patient too 
soon, lengths of stays below the lower limit, called 
low-outliers, obtain a reduced remuneration. 
Conversely, remuneration of high-outliers, with a 
duration above the upper limit, is increased. 
Adjustments are done by increasing or decreasing the 
number of points (cost-weight) per day above or 
below the limits. 
 
Table 1. SDRGs for prosthetic joint infections. 
SDRG Cost-weight Definition 
I03A 
(N=6/21) 2012 : 4.264 2013 : 4.001 Revision or replacement of the articulation of the hip with the diagnosis of complication or 
arthrodesis or age < 16 years or bilateral 
interventions or multiple important interventions 
on the articulations of the legs with complex 
intervention, with extremely severe complications 
or malignant neoplasm 
I03B 
(N=7/21) 2012 : 2.543 2013 : 2.612 Revision or replacement of the articulation of the hip with the diagnosis of complication or 
arthrodesis or age < 16 years or bilateral 
interventions or multiple important interventions 
on the articulation of the legs with complex 
intervention, without extremely severe 
complications or malignant neoplasm 
I04Z 
(N=8/21) 2012 : 2.776 2013 : 3.169 Revision or replacement of the articulation of the knee with the diagnosis of complication or 
arthrodesis 
 
Costs 
The cost is the expense of the hospital for a 
hospital stay. We calculated the costs using a swiss 
standard approach named REKOLE (revision of cost 
accounting and charge capture).[14] It consists of a 
“top-down” cost-analysis where all the costs are 
attributed to the hospitals stays. In it, the annual costs 
directly generated by the patients (material, 
medication, medical fees, etc.) and the indirect costs 
which can not be exclusively imputed to the patients 
(administration, maintenance, etc.) are added. The 
sum of the costs is divided by all the hospital stays 
depending on the resources used. Thus, the cost of a 
hospital stay is calculated by documenting all the 
resources spent [Table 2]. 
Results 
Patients 
37 prosthetic-joint infections were treated with a 
two-stage exchange in the Department of Septic 
Surgery at the University Hospital of Lausanne from 
2012 to 2013. Six patients were excluded because they 
had multiple stays. 10 patients with another SDRG 
were also excluded. 21 patients were included 
[Table 3]. 
 
Table 2. Type of resources used. 
Surgical procedure Cause of costs Cost 
Material and implants Materiel and implants 
used 
Actual prices 
Operating theater Operating theater staff 
time 
Duration of use x cost 
per min 
Anesthesia Anesthesiologist and 
nursing staff time 
Duration of anesthesia x 
cost per min 
Blood Blood transfusions Actual prices 
Imagery Radiological tests Points x point value 
Medical care   
Medication Medication during 
whole stay 
Actual prices 
Medical fees and 
nursing 
Doctors and nursing 
staff time 
Time required x cost per 
min 
Hotel charges and food Hotel charges and food Daily fee 
Intensive care unit Treatment and nursing 
staff time 
Time spent x cost per 
min 
Physiotherapy and 
ergotherapy 
Physiotherapy and 
ergotherapy 
Points x point value 
Laboratory Laboratory tests Points x point value 
Administration   
Management Reception, accounting 
centers and archiving 
Daily fee 
 
Table 3. Patient’s demographic characteristics. 
Total patients 2012-2013 21 
Hip prosthesis 13 
Knee prosthesis   8 
Interval time (weeks, median and range) 3 (1.6-6.3) 
Length of stay (days, median and range 
depending on the infecting agent) 
38 (27-70) 
 
Staphylococcus aureus (N=3) 42 (31-57) 
Coagulase-negative staphylococci (N=7) 38 (31-70) 
Streptococcus spp. (N=4) 31 (28-63) 
Gram-negative rods (N=1) 50 
Cutibacterium acnes (N=2) 39 (36-42) 
Culture-negative PJI (N=4) 35 (27-39) 
Age (median and range) 67 (56-88) 
Male  11 
Female  10 
 
 
Figure 3. Flow of the patients selection. 
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Figure 4. Remuneration computation. 
 
Revenues 
The remuneration for inliers from 2012 to 2013 
ranged from 26'806 to 42'978 CHF (~ 22’905-36’723 
EUR, median 36’338 CHF, ~ 31’049 EUR) depending 
on the SDRG, which is higher than similar 
studies.[13,15] Meanwhile, our hospital stays were 
sometimes up to twice as long than the average length 
for each SDRG (especially in infections with difficult- 
to-treat microorganisms such as methicillin-resistant 
S. epidermidis) [Table 3 and Figure 5]. 
Costs 
The median total cost per patient was 76'000 
CHF (~ 65’000 EUR) (51'151 to 118'263; hip median 
79’744, knee median 66’708), which is similar to costs 
found in other studies.[5–7] The overall costs 
allocation for the 21 patients is reported in Table 4. 
More than two thirds of the costs came from the 
medical care and one third from the surgical 
procedure. The length of the hospital stay generated 
therefore the major part of the costs. 
Comparison between costs and revenues 
The revenues never covered all the costs, even 
with a short interval procedure (< 4 weeks). The 
hospital lost a median of 35’000 CHF per patient (~ 
30’000 EUR) (22'280 to 64'666) [Figure 6]. As the length 
of stay seemed to be the most relevant parameter to 
act on, a simple linear regression was carried out to 
investigate its relationship to the costs. The scatterplot 
showed that there was a linear relationship between 
the two, which was confirmed with the simple linear 
regression (p-value = 0.012). The slope coefficient was 
-411 CHF so the deficit increases by 411 CHF (~ 350 
EUR) for each extra day of hospital stay [Figure 7]. 
The R2 value was 0.332 so 33.2% of the increase in the 
deficit can be explained by the model containing only 
the length of stay. 
 
Table 4. Costs allocation for the 21 patients. 
Surgical procedure (32%) Medical care 
(67%) 
Administration 
(1%) 
13% Material and implants 34% Medication and nursing 1% Management 
12% Operating theater 13% Medical fees  
3% Anesthesia 8% Hotel charges and food  
3% Blood 5% Intensive care unit  
1% Imagery 5% Physiotherapy and 
ergotherapy 
 
 2% Laboratory  
 
Discussion 
We observed that a main determinant of the 
costs was the length of stay. Several options could be 
considered to act on it. The innovative patient hotel 
concept, developed in Scandinavia in the 90s has 
proven to save money while maintaining high-quality 
care.[16–18] Already introduced in other DRG 
countries, the concept offers medical care in a 
private 3-stars hotel structure for patients 
who do not need to be on the acute inpatient 
ward but need to remain nearby the hospital 
for quick access to medical staff. This could 
be an interesting option between the explan-
tation and the reimplantation in two-stage 
exchange to reduce the length of the hospital 
stay. It could also be possible to transfer 
temporally the patient to a rehabilitation 
hospital between the explantation and the 
reimplantation. 
Another cost-saving potential would be 
to refer the patient back home with home 
caring and oral antibiotic therapy between 
the first and second stage of the surgical 
procedure. It has already been done in the 
German DRG system, on which the 
SwissDRG system is based.[13] With this 
solution, a new remuneration could be 
obtained with the second admission, in 
addition to decreasing the length of the 
hospital stay. According the SwissDRG 
 
 
Figure 5. Average revenues per SDRG for 2012 and 2013. 
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system, the rehospitalization would have to take place 
after a period of 18 days in order to be considered as a 
new stay [Figure 8]. We compared the same costs and 
double revenues in a projection of the rehospital-
ization concept. The hospital would break even for 
our sample of patients (slope coefficient = 376 CHF, 
p-value = 0.05, R2 value = 0.214) [Figure 9]. 
It is also crucial to have more specific SDRGs for 
prosthetic-joint infections. The three SDRGs applied 
for treating prosthetic-joint infections include 
uncomplicated cases (e.g. revision without infection) 
and complicated cases (e.g. revision for infection). 
This causes a decrease in the length of the SDRG and 
thus in its ensuring revenues.[19] The German DRG 
system suggest to stratify more by the principal 
diagnosis than the surgical procedure.[13]  
Our study has several limitations. Our research 
focused on the two first years after the introduction of 
the SDRG system because only these two had a 
complete cost-analysis yet from our accounting 
centers. These two years also had a same base rate 
making the analysis more consistent. The cost-weights 
and base rates might have been adjusted since then 
but there is no specific SDRGs for prosthetic-joint 
infections today making our conclusion still topical. 
Moreover, our research was not designed to take 
into account the patient's insurance type (i.e. basic, 
semi-private, private). The only difference is that 
patients with semi-private or private insurances 
(N=5/21) consume more resources in medical fees 
and hotel charges. Hence, the costs could be biased 
and overrated. 
Our conclusion is limited due to the single- 
hospital perspective with a small sample size which 
undermine the external validity of our study. We had 
to exclude patients with multiple stays or with 
another SDRG because we didn’t have the costs from 
other hospitals accounting centers or the remuner-
ation was not the proper one for a prosthetic- 
joint infection. There is a need of studies regarding the 
current economic impact in the healthcare system 
from a nationwide perspective. Additional research 
on prosthetic-joint infections is warranted using 
economic data, such as cost-effectiveness studies. It 
would be interesting to compare different interven-
tions in treating prosthetic-joint infections to 
determine which one may best control infection and 
at the same time lower the economic burden.[20] 
Conclusion 
In summary, this study showed that the current 
SDRG system may not be specific enough for 
rewarding prosthetic-joint infections as revenues 
never covered all the costs. University hospitals 
treating more prosthetic-joint infections than other 
hospitals could be disadvantaged since the 
introduction of the SDRG system.[19] These results 
coincide with other similar studies.[5,13] Several 
options could be considered to act on the length of the 
hospital stay. It is also crucial that the SDRGs would 
be refined in order to reflect better the actual costs. 
 
 
Figure 6. Comparison between costs and revenues. 
 
 
Figure 7. Difference between costs and revenues for each hospital stay. 
 
 
Figure 8. SDRG system for rehospitalization. 
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Figure 9. Difference between costs and double revenues. 
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